{
  "emaEpar": [],
  "fdaDrugLabel": [],
  "id": "Zamtocabtagene_Autoleucel",
  "nciThesaurus": {
    "casRegistry": "",
    "chebiId": "",
    "chemicalFormula": "",
    "definition": "A preparation of autologous CD4/CD8 enriched T-lymphocytes engineered to express pLTG1497, a tandem chimeric antigen receptor (CAR) specific for the two tumor-associated antigens (TAAs) cluster of differentiation 19 (CD19) and CD20, with potential immunostimulating and antineoplastic activities. Upon administration, zamtocabtagene autoleucel target and bind to CD19- and CD20-expressing tumor B-cells. This induces selective toxicity in tumor B-cells expressing these TAAs. Both CD19 and CD20 are B-cell-specific cell surface antigens overexpressed in B-cell lineage malignancies. Targeting both CD19 and CD20 may prevent tumor cell antigen escape and relapse.",
    "fdaUniiCode": "NT3BAN5MDV",
    "identifier": "C180596",
    "preferredName": "Zamtocabtagene Autoleucel",
    "semanticType": "Pharmacologic Substance",
    "subclassOf": [
      "C129826",
      "C137999",
      "C28681"
    ],
    "synonyms": [
      "Autologous Anti-CD20/CD19-targeting Tandem CAR T Cells MB-CART2019.1",
      "Autologous pLTG1497-transduced CAR T-cells MB-CART2019.1",
      "MB CART2019.1",
      "MB-CART2019.1",
      "MBCART2019.1",
      "ZAMTOCABTAGENE AUTOLEUCEL",
      "Zamtocabtagene Autoleucel"
    ]
  }
}